Indeed, evidence suggests that sitagliptin and other DPP-4is are able to reduce daily insulin requirements and improve glucose control without increasing the risk of hypoglycemia or compromising the glucagon counterregulatory response during hypoglycemia in patients with T1D (19,50–52). Here, GCG is linked to type 1 diabetes mellitus.